Publication:
Entecavir Treatment of Chronic Hepatitis D

dc.contributor.authorKabacam, Gokhan
dc.contributor.authorÖNDER, Fatih Oğuz
dc.contributor.authorYakut, Mustafa
dc.contributor.authorSeven, GÜLSEREN
dc.contributor.authorKaratayli, Senem C.
dc.contributor.authorKaratayli, Ersin
dc.contributor.authorSavas, Berna
dc.contributor.authorIdilman, Ramazan
dc.contributor.authorBozdayi, A. Mithat
dc.contributor.authorYurdaydin, Cihan
dc.contributor.institutionauthorSEVEN, GÜLSEREN
dc.date.accessioned2021-01-22T20:59:32Z
dc.date.available2021-01-22T20:59:32Z
dc.date.issued2012-09-01T00:00:00Z
dc.description.abstractBackground. Hepatitis D virus (HDV) requires hepatitis B surface antigen (HBsAg) to propagate infection and cause disease. Entecavir is a nucleoside analog with potent antiviral efficacy, and in the woodchuck animal model it also decreased hepatitis B virus (HBV) cccDNA and woodchuck surface antigen. The aim of this study was to investigate the efficacy of entecavir in chronic hepatitis D (CHD).
dc.identifier.citationKabacam G., ÖNDER F. O. , Yakut M., Seven G., Karatayli S. C. , Karatayli E., Savas B., Idilman R., Bozdayi A. M. , Yurdaydin C., -Entecavir Treatment of Chronic Hepatitis D-, CLINICAL INFECTIOUS DISEASES, cilt.55, ss.645-650, 2012
dc.identifier.doi10.1093/cid/cis459
dc.identifier.scopus84864960836
dc.identifier.urihttp://hdl.handle.net/20.500.12645/28137
dc.identifier.wosWOS:000307498300006
dc.titleEntecavir Treatment of Chronic Hepatitis D
dc.typeArticle
dspace.entity.typePublication
local.avesis.idb377d486-f0cf-4e82-b25b-e3350307d917
local.indexed.atWOS
local.indexed.atScopus
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublicationfedf47e7-d7dd-44db-ada5-60bbaef0ae5b
relation.isAuthorOfPublication.latestForDiscoveryfedf47e7-d7dd-44db-ada5-60bbaef0ae5b
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c

Files

Collections